3-溴-5-氯-2-氟吡啶 | 884494-87-5

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-溴-5-氯-2-氟吡啶
• 中文别名: 2-氟-3-溴-5-氯吡啶；3-溴-2-氟-5-氯吡啶；3-溴-5-氯-2-氟-5-吡啶
• 英文名称: 3-bromo-5-chloro-2-fluoropyridine
• CAS: 884494-87-5
• 化学式: C₅H₂BrClFN
• 分子量: 210.433
• InChiKey: FKHJIEHQWOYVQM-UHFFFAOYSA-N

物化性质

• 沸点：
  204.0±35.0 °C(Predicted)
• 密度：
  1.829±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  T
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Bromo-5-chloro-2-fluoropyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Bromo-5-chloro-2-fluoropyridine
CAS number: 884494-87-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H2BrClFN
Molecular weight: 210.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride, hy-
drogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-溴-5-氯-2-氟吡啶 在 四(三苯基膦)钯 sodium hydride 、 potassium carbonate 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.5h， 生成 5-(4-chloro-3-(4-chloro-phenyl)-2-(S)-2,2,2-trifluoro-1-methyl-ethoxy)-pyridine
  参考文献：
  名称：

  [EN] N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES
  [FR] N-PYRIDIN-3-YL- OU N-PYRAZIN-2-YL-CARBOXAMIDES

  摘要：

  本发明涉及公式I的化合物，其中A，R1至R7在描述中有定义，并且其药学上可接受的盐，它们的制备，含有它们的药物组合物以及它们作为治疗和/或预防可用高密度脂蛋白胆固醇升高剂治疗的疾病的药物的用途，如特别是脂质代谢异常，动脉粥样硬化和心血管疾病。

  公开号：

  WO2012049190A1

文献信息

• Discovery of DS-6930, a potent selective PPARγ modulator. Part II: Lead optimization
  作者：Tsuyoshi Shinozuka、Tomoharu Tsukada、Kunihiko Fujii、Eri Tokumaru、Kousei Shimada、Yoshiyuki Onishi、Yumi Matsui、Satoko Wakimoto、Masanori Kuroha、Tsuneaki Ogata、Kazushi Araki、Jun Ohsumi、Ryoko Sawamura、Nobuaki Watanabe、Hideki Yamamoto、Kazunori Fujimoto、Yoshiro Tani、Makoto Mori、Jun Tanaka

  DOI：10.1016/j.bmc.2018.09.005

  日期：2018.10

  synthesized compound (II) for the avoidance of hepatotoxicity. The replacement of the left-hand side benzene with 2-pyridine resulted in the substantial loss of potency. Because poor membrane permeability was responsible for poor potency in vitro, the adjustment of lipophilicity was examined, which resulted in the discovery of dimethyl pyridine derivative (I, DS-6930). In preclinical studies, DS-6930 demonstrated

  为了避免肝毒性，尝试降低先前合成的化合物（II）的亲脂性。用2-吡啶代替左手侧苯导致效力的实质损失。由于差的膜通透性导致体外效价差，因此对亲脂性的调节进行了检查，从而发现了二甲基吡啶衍生物（I，DS-6930）。在临床前研究中，DS-6930表现出较高的PPARγ激动剂效价，且血浆葡萄糖降低明显。DS-6930在体内进行毒理学评估后维持与PPARγ相关的副作用减少，并没有显示出肝毒性。辅助因子募集测定表明，显着募集了一些辅助因子，例如RIP140和PGC1，而几个典型因子并未受到影响。这种选择性辅因子募集是由于DS-6930的独特结合模式引起的。钙盐DS-6930b被认为是有效的胰岛素增敏剂，无水肿，可在T2DM患者中进行临床评估。
• Metal-free site-selective C–N bond-forming reaction of polyhalogenated pyridines and pyrimidines
  作者：Lei Wang、Ning Liu、Bin Dai

  DOI：10.1039/c5ra18653f

  日期：——

  of the pyridine ring to generate monosubstituted halogenated pyridines with high selectivities. Different halogen atoms at various positions were produced by the pyridine ring that performed well under mild conditions. Halogenated pyrimidines underwent highly selective coupling at the chloride group with a wide range of amines having broad substrate applicability and moderate to good yields. The selectivity

  本文提出了一种多金属的方法，用于多位卤代吡啶和嘧啶的高位点选择性C–N键形成反应。当从吡啶环变为嘧啶环时，优选的偶联位点可从带有N-杂环的氟基团调节至氯基团。各种各样的卤代吡啶优先与吡啶环氟原子上的胺反应，生成具有高选择性的单取代卤代吡啶。吡啶环在不同位置产生了不同的卤素原子，这些吡啶环在温和的条件下表现良好。卤代嘧啶在氯化物基团上与多种胺进行高度选择性的偶联，这些胺具有广泛的底物适用性并且产率中等至良好。氮环的邻位。该反应容纳了广泛的卤代基团。因此，产生了大量的氯，溴，碘和氟吡啶，它们对于有机合成具有广泛的用途。
• 螺环2,3-二氢-7-氮杂吲哚化合物及其用途
  申请人：豪夫迈·罗氏有限公司

  公开号：CN113015526A

  公开（公告）日：2021-06-22

  本发明提供式(I)的螺环2,3‑二氢‑7‑氮杂吲哚化合物：所述式的变体的所述化合物，以及所述化合物作为HPK1(造血激酶1)抑制剂的用途。所述化合物可用于治疗HPK1依赖性疾患以及增强免疫应答。本公开还描述了抑制HPK1的方法、治疗HPK1依赖性疾患的方法、用于增强免疫应答的方法以及用于制备所述螺环2,3‑二氢‑7‑氮杂吲哚化合物的方法。
• Access to 2-pyridinylamide and imidazopyridine from 2-fluoropyridine and amidine hydrochloride
  作者：Yibiao Li、Shuo Huang、Jiaming Li、Jian Li、Xiaoliang Ji、Jiasheng Liu、Lu Chen、Shiyong Peng、Kun Zhang

  DOI：10.1039/d0ob01904f

  日期：——

  Under catalyst-free conditions, an efficient method to synthesize 2-pyridinylamides has been developed, and the protocol uses inexpensive and readily available 2-fluoropyridine and amidine derivatives as the starting materials. Simultaneously, the copper-catalysed approach to imidazopyridine derivatives has been established with high chemoselectivity and regiospecificity. The results suggest that the

  在无催化剂条件下，开发了一种合成 2-吡啶酰胺的有效方法，该协议使用廉价且易于获得的 2-氟吡啶和脒衍生物作为起始材料。同时，铜催化的咪唑并吡啶衍生物方法已被建立，具有高化学选择性和区域特异性。结果表明，含有碘化物取代基的氮杂环也可以通过级联Ullmann型偶联与反应相容，并且亲核取代反应以一锅方式提供目标产物。
• [EN] BROMODOMAIN INHIBITORS<br/>[FR] INHIBITEURS DE BROMODOMAINE
  申请人：ABBVIE INC

  公开号：WO2015085925A1

  公开（公告）日：2015-06-18

  The present invention provides for compounds of formula (I) wherein Rx, X, Y, Y1, L1, A1, A2, A3, A4, A5, A6, A7, and A8, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了一种具有以下式（I）的化合物，其中Rx、X、Y、Y1、L1、A1、A2、A3、A4、A5、A6、A7和A8具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物可用作治疗疾病和病况的药剂，包括炎症性疾病、癌症和艾滋病的药剂。还提供了由一种或多种式（I）化合物组成的药物组合物。